Physician profile
Arienne Morrow
NPI 1730967274
$1,525.85
in general payments reported to CMS, 2019-2025
13 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $90.83 · 2024: $1,327 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486 · Education: $39.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.24 |
| Education | $39.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $281.06 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $260.40 | 2024 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $208.02 | 2024-2025 | Terlivaz, Acthar |
| Otsuka America Pharmaceutical, INC. | $196.84 | 2024 | Jynarque |
| Ardelyx, INC. | $132.14 | 2024 | Xphozah 30 Mg, Ibsrela |
| Abbvie INC. | $118.74 | 2024 | |
| Alnylam Pharmaceuticals INC. | $90.83 | 2023 | Oxlumo |
| Travere Therapeutics, INC. | $55.49 | 2024 | |
| Amgen INC. | $50.34 | 2024 | Parsabiv, Aranesp, Tavneos |
| Fresenius USA Marketing, INC. | $45.55 | 2024 | Velphoro |
| Opko Pharmaceuticals, LLC | $39.61 | 2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $29.24 | 2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.59 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arienne Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.